# US 2025/0375406 A1 · Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375406 A1
- Document ID: US20250375406A1
- Status: Published application
- Kind: A1
- Application number: 18/874,384
- Filed: 2023-06-26
- Published: 2025-12-11
- Earliest claimed: 2022-06-24
- Applicants: Veroscience LLC
- Inventors: Anthony H. Cincotta
- Web page: https://patentgrep.com/patent/US20250375406A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/12: Ketones
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided. Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided.

## Claims

### Claim at position 1

-36. (canceled)

### Claim 37

A method of treating non-alcoholic steatohepatitis (NASH) in a subject in need thereof, which comprises administering to a subject in need of such treatment a biological source of L-DOPA,-pantethine, and curcumin, said co-administration taking place between 0400 and 1200 hours.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject is also afflicted with a metabolic disorder selected from the group consisting of obesity, prediabetes, glucose intolerance, hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease associated with NASH, comprising administering to a subject in need of such treatment Mucuna pruriens containing L-DOPA, pantethine, and optionally solubilized curcumin, said co-administration taking place within 4 hours of waking in the morning wherein the formulation treats the metabolic disorder and the NASH.

### Claim 39 (depends on 37)

The method of claim 37, wherein the biological source of L-DOPA is broad bean or Mucuna pruriens.

### Claim 40 (depends on 37)

The method of claim 37, wherein the biological source of L-DOPA is Mucuna pruriens delivered at between 6 and 150 mg/kg.

### Claim 41 (depends on 38)

The method of claim 38, wherein the curcumin is solubilized curcumin.

### Claim 42 (depends on 41)

The method of claim 41, wherein the solubilized curcumin comprises a mixture of phosphatidylcholine, caprylic/capric triglyceride, alcohol, glyceryl stearate, oleic acid, ascorbyl palmitate, and tocopherol.

### Claim 43 (depends on 42)

The method of claim 42, which comprises administering the curcumin to the subject in an amount of between about 0.1 mg/kg to about 0.07 g/kg of body weight per day.

### Claim 44 (depends on 42)

The method of claim 42, which further comprises administering a probiotic to the subject.

### Claim 45 (depends on 38)

The method of claim 38, wherein the formulation delivers a dosage of between 1 and 20 mg/kg body weight of L-DOPA, between 5 and 100 mg/kg body weight pantethine, and between 2 and 30 mg/kg body weight curcumin.

### Claim 46 (depends on 38)

The method of claim 38, wherein the formulation comprises at least one solid dosage form.

### Claim 47 (depends on 46)

The method of claim 46, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule or a powder.

### Claim 48

A pharmaceutical dosage comprising a biological source of L-DOPA, pantethine and curcumin.

### Claim 49 (depends on 48)

The pharmaceutical dosage of claim 48, wherein the dosage is in the form of a tablet, a capsule or a powder.

### Claim 50 (depends on 49)

The pharmaceutical dosage of claim 49, wherein the curcumin is solubilized and includes a mixture of phosphatidylcholine, caprylic/capric triglyceride, alcohol, glyceryl stearate, oleic acid, ascorbyl palmitate, and tocopherol.

### Claim 51 (depends on 48)

The pharmaceutical dosage of claim 48, comprising between 20 and 2000 mg L-DOPA, between 100 and 1500 mg pantethine, between 2 and 2,000 mg curcumin and a binder.

### Claim 52 (depends on 48)

The pharmaceutical dosage of claim 48, wherein the biological source of L-DOPA is Mucuna Pruriens extract.

### Claim 53 (depends on 52)

The pharmaceutical dosage of claim 52, comprising Mucuna pruriens extract in an amount between 120 and 5000 mg., pantethine in an amount between 100 and 1500 m, solubilized curcumin in an amount between 2 and 2000 mg; and a binder.

### Claim 54

A method of treating metabolic disorders in a subject in need thereof which comprises co-administering to a subject in need of such treatment in a single formulation or separately (i) Mucuna pruriens containing L-DOPA, (ii) pantethine, and (ii) curcumin, said co-administration taking place within 4 hours of waking in the morning.

### Claim 55 (depends on 54)

The method of claim 54, wherein the metabolic disorder is pre-diabetes.

### Claim 56 (depends on 54)

The method of claim 54, wherein the metabolic disorder is hypertension.
